Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Phreesia ( (PHR) ) just unveiled an update.
On June 25, 2025, Phreesia, Inc. held its annual stockholders’ meeting where three proposals were voted on. The stockholders elected two directors, Gillian Munson and Mark Smith, M.D., for a three-year term. Additionally, the appointment of KPMG LLP as the independent registered public accounting firm was ratified, and the compensation of named executive officers was approved on a non-binding, advisory basis.
The most recent analyst rating on (PHR) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Phreesia stock, see the PHR Stock Forecast page.
Spark’s Take on PHR Stock
According to Spark, TipRanks’ AI Analyst, PHR is a Neutral.
Phreesia’s stock score is primarily supported by strong revenue growth and improving cash flows, as highlighted in the earnings call. However, ongoing profitability challenges and valuation concerns, including a negative P/E ratio, weigh down the overall score. Technical indicators present a mixed outlook, further contributing to the moderate score.
To see Spark’s full report on PHR stock, click here.
More about Phreesia
Phreesia, Inc. operates in the healthcare industry, providing patient intake management solutions. The company focuses on streamlining the patient intake process for healthcare providers, enhancing operational efficiency and patient experience.
Average Trading Volume: 532,612
Technical Sentiment Signal: Buy
Current Market Cap: $1.61B
See more insights into PHR stock on TipRanks’ Stock Analysis page.